Home > Newsletters > Drug Industry Daily > J&J Suspends Three Trials of Experimental Dermatitis Drug Due to Adverse Events
Drug Industry Daily
Sept. 17, 2012 | Vol. 11 No. 182
J&J Suspends Three Trials of Experimental Dermatitis Drug Due to Adverse Events
Johnson & Johnson (J&J) has halted two Phase II clinical trials and withdrawn plans for another after two patients receiving an experimental dermatitis drug experienced serious adverse events.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.